Logo

Sun Pharma's SPARC Signs a Research Collaboration with HitGen to Develop Therapies

Share this

Sun Pharma's SPARC Signs a Research Collaboration with HitGen to Develop Therapies

Shots:

  • HitGen to receive upfront & milestones and will utilize its DNA-encoded library design technology to develop therapies for Sun Pharma’s SPARC targets
  • The focus of the collaboration is to combine the SPARC’s research expertise with HitGen’s DELs based screening technology to develop therapies for serious medical conditions 
  • HitGen’s DELs is a platform for small molecule drug discovery including 400B macrocyclic compounds developing biological targets. The company has also collaborated with other companies & foundations in North America- Europe- Asia & Africa to discover therapies & agrochemical solutions

Ref: HitGen | Image: Livemint

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions